(2004067542)

19/11/04

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number
WO 2003/099231 A3

(51) International Patent Classification[7]: A61K 31/505

(21) International Application Number:
PCT/US2003/017150

(22) International Filing Date: 27 May 2003 (27.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/383,244 24 May 2002 (24.05.2002) US

(71) Applicant *(for all designated States except US)*: **ELAN PHARMACEUTICALS, INC.** [US/US]; 800 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KONRADI, Andrei, W.** [US/US]; 30 Victoria Road, Burlingame, CA 94010 (US). **SEMKO, Christopher, M.** [US/US]; 4993 Norris Road, Fremont, CA 94536 (US). **XU, Ying-zi** [CN/US]; 793 Cereza Drive, Palo Alto, CA 94306 (US). **STAPPENBECK, Frank** [US/US]; 1342 26th Avenue, Apt. 3, San Francisco, CA 94122 (US). **STUPI, Brian, P.** [US/US]; 421 Terrace Avenue, P.O. Box 239, Moss Beach, CA 94038 (US). **SMITH, Jenifer** [US/US]; 712 A Central Avenue, San Francisco, CA 94117 (US). **THORSETT, Eugene, D.** [US/US]; 326 Purissima Street, Half Moon Bay, CA 94019 (US).

(74) Agent: **SWISS, Gerald, R.**; Burns, Doane, Swecker & Mathis, LLP, P.O. Box 1404, Alexandria, VA 22313-1404 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
22 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

ACTION

(54) Title: HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS

(57) Abstract: Disclosed are compounds which bind 4 integrins, where the 4integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by 4integrins, where the 4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

WO 2003/099231 A3